Effect of Various Invitation Schemes on the Use of Fecal Immunochemical Tests for Colorectal Cancer Screening: Protocol for a Randomized Controlled Trial

被引:1
|
作者
Gruner, Laura Fiona [1 ,2 ]
Hoffmeister, Michael [1 ]
Ludwig, Leopold [3 ]
Brenner, Hermann [1 ,4 ,5 ,6 ]
机构
[1] German Canc Res Ctr, Div Clin Epidemiol & Aging Res, Neuenheimer Feld 581, D-69120 Heidelberg, Germany
[2] Heidelberg Univ, Med Fac Heidelberg, Heidelberg, Germany
[3] Gastroentereol Schwerpunktpraxis, Dornstadt, Germany
[4] German Canc Res Ctr, Div Prevent Oncol, Heidelberg, Germany
[5] Natl Ctr Tumor Dis, Heidelberg, Germany
[6] German Canc Res Ctr, German Canc Consortium, Heidelberg, Germany
来源
JMIR RESEARCH PROTOCOLS | 2020年 / 9卷 / 04期
关键词
colorectal cancer; early detection; screening; fecal immunochemical test (FIT); invitation; Germany; PARTICIPATION;
D O I
10.2196/16413
中图分类号
R19 [保健组织与事业(卫生事业管理)];
学科分类号
摘要
Background: Fecal occult blood testing has been offered for many years in the German health care system, but participation rates have been notoriously low. Objective: The aim of this study is to evaluate the effect of various personal invitation schemes on the use of fecal immunochemical tests (FITs) in persons aged 50-54 years. Methods: This study consists of a three-armed randomized controlled trial: (1) arm A: an invitation letter from a health insurance plan including a FIT test kit, (2) arm B: an invitation letter from a health insurance plan including an offer to receive a free FIT test kit by mail upon easy-to-handle request (ie, by internet, fax, or reply mail), and (3) arm C: an information letter on an existing colonoscopy offer (ie, control). Within arms A and B, a random selection of 50% of the study population will receive reminder letters, the effects of which are to be evaluated in a substudy. Results: A total of 17,532 persons aged 50-54 years in a statutory health insurance plan in the southwest of Germany-AOK Baden-Wuerttemberg-were sent an initial invitation, and 5825 reminder letters were sent out. The primary end point is FIT usage within 1 year from receipt of invitation or information letter. The main secondary end points include gender-specific FIT usage within 1 year, rates of positive test results, rates of colonoscopies following a positive test result, and detection rates of advanced neoplasms. The study was launched in September 2017. Data collection and workup were completed in fall 2019. Conclusions: This randomized controlled trial will provide important empirical evidence for enhancing colorectal cancer screening offers in the German health care system.
引用
收藏
页数:9
相关论文
共 50 条
  • [41] A study protocol for the CHinA National CancEr screening (CHANCES) trial: a randomized controlled study to compare the screening strategies for lung cancer and colorectal cancer
    Yibo Gao
    Ping Hu
    Ning Wu
    Fengwei Tan
    Wei Cao
    Wei Tang
    Fei Wang
    Jiang Li
    Xin Li
    Yan Wen
    Yongjie Xu
    Yiwen Yu
    Chao Qin
    Xuesi Dong
    Jiansong Ren
    Zhuoyu Yang
    Yadi Zheng
    Zheng Wu
    Paul Pinsky
    Philip Prorok
    Martina Taylor
    Ni Li
    Barnett Kramer
    Jie He
    BMC Cancer, 25 (1) : 727
  • [42] Comparison of mailed invitation strategies to improve fecal occult blood test participation in men: protocol for a randomized controlled trial
    Duncan, Amy
    Zajac, Ian
    Flight, Ingrid
    Stewart, Benjamin J. R.
    Wilson, Carlene
    Turnbull, Deborah
    TRIALS, 2013, 14
  • [43] A randomized controlled trial of a multicomponent, targeted, low-literacy educational intervention compared with a nontargeted intervention to boost colorectal cancer screening with fecal immunochemical testing in community clinics
    Davis, Stacy N.
    Christy, Shannon M.
    Chavarria, Enmanuel A.
    Abdulla, Rania
    Sutton, Steven K.
    Schmidt, Alyssa R.
    Vadaparampil, Susan T.
    Quinn, Gwendolyn P.
    Simmons, Vani N.
    Ufondu, Chukwudi B.
    Ravindra, Chitra
    Schultz, Ida
    Roetzheim, Richard G.
    Shibata, David
    Meade, Cathy D.
    Gwede, Clement K.
    CANCER, 2017, 123 (08) : 1390 - 1400
  • [44] False-positive fecal immunochemical test results in colorectal cancer screening and gastrointestinal drug use
    M. J. Domper Arnal
    S. García Mateo
    S. Hermoso-Durán
    D. Abad
    P. Carrera-Lasfuentes
    A. Velazquez-Campoy
    O. Abian Franco
    A. Lanas
    International Journal of Colorectal Disease, 2021, 36 : 1861 - 1869
  • [45] A feces collection paper does not enhance participation in a fecal immunochemical test-based colorectal cancer screening program: randomized clinical trial
    Denters, Maaike J.
    Deutekom, Marije
    Bossuyt, Patrick M.
    Fockens, Paul
    Dekker, Evelien
    EUROPEAN JOURNAL OF CANCER PREVENTION, 2013, 22 (04) : 299 - 304
  • [46] Improving adherence to surveillance and screening recommendations for people with colorectal cancer and their first degree relatives: a randomized controlled trial
    Carey, Mariko
    Sanson-Fisher, Rob
    Macrae, Finlay
    Hill, David
    D'Este, Catherine
    Paul, Christine
    Doran, Christopher
    BMC CANCER, 2012, 12
  • [47] Bounding the per-protocol effect in randomized trials: an application to colorectal cancer screening
    Sonja A. Swanson
    Øyvind Holme
    Magnus Løberg
    Mette Kalager
    Michael Bretthauer
    Geir Hoff
    Eline Aas
    Miguel A. Hernán
    Trials, 16
  • [48] FECAL OCCULT BLOOD SCREENING FOR COLORECTAL NEOPLASIA - A RANDOMIZED TRIAL OF 3 DAYS OR 6 DAYS OF TESTS
    THOMAS, WM
    PYE, G
    HARDCASTLE, JD
    MANGHAM, CM
    BRITISH JOURNAL OF SURGERY, 1990, 77 (03) : 277 - 279
  • [49] Text Messaging Versus Postal Reminders to Improve Participation in a Colorectal Cancer Screening Program: Randomized Controlled Trial
    Vives, Nuria
    Binefa, Gemma
    Travier, Noemie
    Farre, Albert
    Panera, Jon Aritz
    Casas, Berta
    Vidal, Carmen
    Ibanez-Sanz, Gemma
    Garcia, Montse
    JMIR MHEALTH AND UHEALTH, 2025, 13
  • [50] Bounding the per-protocol effect in randomized trials: an application to colorectal cancer screening
    Swanson, Sonja A.
    Holme, Oyvind
    Loberg, Magnus
    Kalager, Mette
    Bretthauer, Michael
    Hoff, Geir
    Aas, Eline
    Hernan, Miguel A.
    TRIALS, 2015, 16